Coronavirus disease (COVID-19)
The European Medicines Agency (EMA) is contributing to global efforts to save lives during the COVID-19 pandemic by expediting the development and approval of safe and effective treatments and vaccines, supporting the continued availability of medicines in the European Union (EU), and providing reliable information to patients and healthcare professionals.
Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus.
On 30 January 2020, the World Health Organization (WHO) declared the outbreak a public health emergency of international concern. On 11 March 2020, WHO characterised COVID-19 as a pandemic.
There are currently several potential COVID-19 treatments and vaccines undergoing clinical trials.
The COVID-19 EMA pandemic Task Force is the main tool of EMA and the European medicines regulatory network for enabling EU Member States and the European Commission to take quick and coordinated regulatory action during the pandemic.
-
List item
What’s new
Our latest updates on the COVID-19 pandemic, including our news and press releases
-
List item
Guidance for medicine developers and companies
Regulatory mechanisms to speed up medicine and vaccine development and approval and advice on clinical trials and regulatory expectations
-
List item
Treatments and vaccines for COVID-19
Information on potential treatments and vaccines under investigation, including ongoing clinical trials and observational studies in the EU
-
List item
Availability of medicines
EU measures to help prevent and mitigate supply disruptions and medicine shortages during the pandemic
-
List item
Public-health advice
Advice for patients and healthcare professionals on the safe use of medicines during the pandemic, in particular in patients with or at risk of COVID-19 infection
-
List item
EMA's governance
Our governance during the COVID-19 pandemic, including the role and activities of the COVID-19 EMA pandemic Task Force